CN113215045B - Lactobacillus gasseri LGV03 and application thereof - Google Patents
Lactobacillus gasseri LGV03 and application thereof Download PDFInfo
- Publication number
- CN113215045B CN113215045B CN202110523517.9A CN202110523517A CN113215045B CN 113215045 B CN113215045 B CN 113215045B CN 202110523517 A CN202110523517 A CN 202110523517A CN 113215045 B CN113215045 B CN 113215045B
- Authority
- CN
- China
- Prior art keywords
- lgv03
- lactobacillus gasseri
- tryptase
- vivo
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186606 Lactobacillus gasseri Species 0.000 title claims abstract description 45
- 230000001580 bacterial effect Effects 0.000 claims abstract description 18
- 210000003630 histaminocyte Anatomy 0.000 claims abstract description 17
- 239000000725 suspension Substances 0.000 claims abstract description 16
- 238000004321 preservation Methods 0.000 claims abstract description 4
- 208000026935 allergic disease Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 102000001400 Tryptase Human genes 0.000 abstract description 22
- 108060005989 Tryptase Proteins 0.000 abstract description 22
- 238000000855 fermentation Methods 0.000 abstract description 13
- 230000004151 fermentation Effects 0.000 abstract description 13
- 239000006228 supernatant Substances 0.000 abstract description 13
- 238000001727 in vivo Methods 0.000 abstract description 10
- 241000252212 Danio rerio Species 0.000 abstract description 9
- 208000003455 anaphylaxis Diseases 0.000 abstract description 8
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 7
- 244000005700 microbiome Species 0.000 abstract description 7
- 230000004936 stimulating effect Effects 0.000 abstract description 6
- 229920002055 compound 48/80 Polymers 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 description 18
- 239000006041 probiotic Substances 0.000 description 11
- 235000018291 probiotics Nutrition 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000000529 probiotic effect Effects 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 7
- 208000004262 Food Hypersensitivity Diseases 0.000 description 6
- 239000006161 blood agar Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000020932 food allergy Nutrition 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 206010016946 Food allergy Diseases 0.000 description 5
- 241000186781 Listeria Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 229960002227 clindamycin Drugs 0.000 description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 4
- 229960003907 linezolid Drugs 0.000 description 4
- 229960002260 meropenem Drugs 0.000 description 4
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 229960000265 cromoglicic acid Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010058285 Allergy to arthropod bite Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- DEOKFPFLXFNAON-UHFFFAOYSA-N N-α-Benzoyl-DL-arginine 4-nitroanilide hydrochloride Chemical compound Cl.C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(CCCN=C(N)N)NC(=O)C1=CC=CC=C1 DEOKFPFLXFNAON-UHFFFAOYSA-N 0.000 description 1
- 241000272041 Naja Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000037446 allergic sensitization Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000000270 postfertilization Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a Lactobacillus gasseri LGV03 and application thereof, belonging to the technical field of microorganisms. The preservation number of the Lactobacillus gasseri LGV03 is CGMCC No.22010. Fermentation supernatant and bacterial suspension of the Lactobacillus gasseri LGV03 can obviously inhibit Compound 48/80 from stimulating the zebra fish to secrete Tryptase in vivo, can inhibit degranulation of mast cells in vivo, and has the potential of being applied to preventing anaphylactic reaction in vivo. The lactobacillus gasseri LGV03 disclosed by the invention has a huge potential application prospect in the aspect of preventing anaphylactic reaction.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to a lactobacillus gasseri LGV03 and application thereof.
Background
Allergic diseases are becoming a global public health problem, and various allergic diseases including asthma, allergic rhinitis and conjunctivitis, drug allergy, food allergy, insect bite allergy, skin eczema (atopic dermatitis), urticaria or severe systemic anaphylaxis (anaphylactic shock) affect people's health and daily life to various degrees, and some serious cases even endanger life, both in developed countries and developing countries. Therefore, allergic diseases are classified as one of three major diseases which are mainly prevented and treated in the 21 st century. According to epidemiological investigations worldwide, about 22% of the population suffers from different kinds of allergic diseases.
Allergy is a hypersensitivity reaction to harmless environmental antigens such as pollen and food. Typical anaphylaxis is when allergen induces Th2 cell to secrete IL-4, IL-5, IL-10 and IL-13, which can effectively activate B cell to produce IgE antibody, igE is combined with mast cell, and the mast cell degranulation is caused to release serine protease, histamine, cytokine and other mediators, and the anaphylaxis against specific antigen is initiated. Studies have shown that mast cells, a key effector cell in allergic reactions, secrete not only inflammatory mediators but also considerable amounts of various cytokines upon antigen activation of specific signal transduction pathways, and play a critical role in the development and progression of allergic diseases. Tryptase (Tryptase) is an important protease in mast cells, and it is similar to trypsin. Tryptase (Tryptase) is a specific marker for identifying human mast cells because storage and expression in mast cells are highly selective and cannot be detected in other cell types. In addition, tryptase (Tryptase) can be released extracellularly by degranulation of mast cells, and therefore, extracellular Tryptase (Tryptase) can serve as a marker for activation and degranulation of mast cells.
At present, the means for treating allergic diseases is limited, and only some antiallergic medicines are taken at the time of the disease, so that the occurrence of allergic reaction cannot be completely avoided. With the increasingly intensive scientific research on intestinal microorganisms, the relationship between intestinal microorganisms and health is receiving more and more attention from people, especially the relationship between intestinal microorganisms and allergy. It has been shown that food allergy is associated with the microbial composition of the intestine, and that certain bacteria in the intestine protect humans from food allergy. Thus, intervention in the gut microflora may provide a new strategy for preventing allergic sensitization.
Probiotics are defined as living microorganisms that improve the balance of the intestinal flora and may benefit various aspects of the physiological response of the host, including immune function. In addition, the prevention and treatment effects of probiotics on allergic diseases such as atopic dermatitis, allergic rhinitis, food allergy, etc. have also been studied in a large amount. There have been several studies showing that oral administration of bifidobacteria or lactobacilli can reduce food allergies. Lactobacillus can attenuate mast cell activation and release inflammatory mediators associated with allergic reactions. The bifidobacterium BGN4 can inhibit the generation of serum IgE and IgG1 in a food allergy mouse model, and in addition, the lactobacillus casei Shirota can inhibit the generation of antigen-specific IgE by stimulating the secretion of IL-12, so that the lactobacillus casei Shirota shows good probiotic efficacy for preventing or treating allergic diseases. The current international probiotic patent application focuses on the traditional research and development strong countries in the United states, the Japan and the Russia, and China lacks functional strains with independent intellectual property rights. Probiotic strains used by domestic production enterprises are imported for a long time, and foreign strains are not necessarily suitable for the gastrointestinal physiological conditions of residents in China. In addition, the function of the probiotics lacks strong scientific research evidence, and the popularization of the probiotics and the products thereof is seriously influenced. Based on the method, aiming at the deep excavation of the functions of the strain resources, the novel probiotic strain which has independent intellectual property rights, has specific functional properties and is suitable for the physiological characteristics of Chinese people is screened out, and the method is particularly important for improving the core competitiveness of probiotic production enterprises in China and promoting the development of probiotic products in China.
Therefore, the problem to be solved by the technical personnel in the field is to provide the lactobacillus gasseri LGV03 and the application thereof.
Disclosure of Invention
In view of the above, the invention provides a lactobacillus gasseri LGV03 and application thereof in preparing a medicament for preventing allergic diseases.
In order to achieve the purpose, the invention adopts the following technical scheme:
the lactobacillus gasseri (Lactobacillus gasseri) LGV03 has the preservation number of CGMCC No.22010, is preserved in the China general microbiological culture Collection center of China Committee for culture Collection of microorganisms (CGMCC for short), is collected at China academy of sciences institute of China No.3, beijing, naja, north Cheng Yang district, xilu No. 1, has the preservation date of 2021 year, 03 month and 15 days, and is classified and named as Lactobacillus gasseri.
Further, the Lactobacillus gasseri LGV03 is applied to preparation of a medicament for preventing allergic diseases.
Further, the Lactobacillus gasseri LGV03 is applied to preparation of medicines for inhibiting mast cell degranulation.
Further, the lactobacillus gasseri LGV03 is a bacterial suspension or a fermentation supernatant.
The Lactobacillus gasseri LGV03 disclosed by the invention has the effect of inhibiting Compound 48/80 from stimulating Tryptase secretion of zebra fish in vivo, has the potential of inhibiting mast cell degranulation, and shows a good probiotic effect of preventing anaphylactic reaction.
The bacterial strain capable of remarkably inhibiting Compound 48/80 from stimulating the zebra fish to secrete Tryptase in vivo comprises fermentation supernatant (extracellular secretion) and bacterial suspension (thallus) of the bacterial strain.
According to the technical scheme, compared with the prior art, the invention discloses and provides the Lactobacillus gasseri LGV03 and the application thereof in preparing the medicament for preventing the allergic diseases, the Lactobacillus gasseri LGV03 is obtained by separating and screening the secretion of the genital tract of a healthy female, can obviously inhibit Compoud48/80 from stimulating the secretion of Tryptase by zebra fish in vivo, can inhibit the degranulation of mast cells in vivo, has the potential of being applied to the in vivo prevention of the allergic reaction, and provides theoretical reference and guidance basis for developing the probiotic preparation for preventing the allergic reaction by utilizing the Lactobacillus gasseri LGV 03.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the embodiments or the prior art descriptions will be briefly described below, it is obvious that the drawings in the following description are only embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the provided drawings without creative efforts.
FIG. 1 is a phylogenetic tree of the 16SrDNA sequences of Lactobacillus gasseri LGV03 and related species according to the invention;
FIG. 2 is a diagram showing the morphology of colonies formed by Lactobacillus gasseri LGV03 on MRS solid medium;
FIG. 3 is a drawing showing the colony morphology of Lactobacillus gasseri LGV03 on a blood agar plate according to the present invention;
wherein, 1, negative control bacterium: CICC10417 listeria inorage; 2, positive control bacteria: cic 10473 staphylococcus aureus; 3, sample: lactobacillus gasseri LGV03;
FIG. 4 is a drawing showing the microscopic morphology observation of the Lactobacillus gasseri LGV03 after gram-staining;
FIG. 5 is a drawing showing the drug sensitivity test of Lactobacillus gasseri LGV03 of the present invention;
wherein, A: penicillin; b: ampicillin; c: meropenem; d: vancomycin; e: erythromycin; f: clindamycin; g: linezolid;
FIG. 6 is a graph showing the effect of fermentation supernatant, bacterial suspension of Lactobacillus gasseri LGV03 of the present invention on the expression level of Compoud48/80 stimulating Tryptase secretion from zebrafish;
FIG. 7 is a graph showing the inhibition rate of fermented supernatant and bacterial suspension of Lactobacillus gasseri LGV03 on the secretion of Tryptase stimulated by Compoud48/80 zebra fish.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1 isolation and identification of Lactobacillus gasseri LGV03
(1) Separation: the genital secretion of healthy women is diluted in a gradient way, and then is respectively inoculated in a TPY solid culture medium, an MRS solid culture medium, a BDS solid culture medium and a BS solid culture medium, anaerobic culture is carried out for 48 hours at 37 ℃, and a single colony on a flat plate is picked and streaked to obtain a pure colony. Inoculating pure bacterial colonies on the plate into an MRS liquid culture medium, carrying out anaerobic culture at 37 ℃ for 12-16 h, adding 20% glycerol, and storing in a refrigerator at-80 ℃.
(2) Molecular biological identification of the strains: extracting genome DNA of the obtained strain, amplifying a 16SrDNA full-length fragment by using 16SrDNA universal primers 27F and 1492R through a PCR technology, and then sequencing to identify the strain species. Wherein the sequences of the universal primers 27F and 1492R are as follows:
27F:5’-AGAGTTTGATCCTGGCTCAG-3’;SEQ ID NO.1;
1492R:5’-GGTTACCTTGTTACGACTT-3’;SEQ ID NO.2。
physiological and biochemical identification of the strain: the colonies were picked to prepare a bacterial suspension and identified with a VITEKANC identification card. The specific physiological and biochemical results are shown in Table 1.
TABLE 1LGV03 physiological and biochemical reaction results
Description of the symbols: "+", positive; "+ w ", weak positive; "-", negative.
Phylogenetic analysis: the MEGA software and the adjacent position connection method are adopted to display the 'Lactobacillus gasseri LGV 03' and a 16SrDNA sequence phylogenetic tree of related species, the similarity is repeatedly calculated for 1000 times, the nodes of the phylogenetic tree in the figure only display Bootstrap values larger than 50% of values, and the superscript 'T' represents a model strain.
The experimental results are as follows: the strains selected from the secretions of the genital tract of healthy women in Guangzhou, guangdong province were analyzed by systematic evolution using MEGA software on the basis of 16SrDNA homology for 11 typical strains, and the results are shown in FIG. 1.LGV03 and Lactobacillus gasseri model strain ATCC33323 T (CP 000413) constitutes a branch alone, reflecting that the relationship between the two is recent. Thus, strain LGV03 was identified as Lactobacillus gasseri by biochemical and physiological identification, 16SrDNA identification and phylogenetic tree showing that its 16SrDNA sequence is shown in SEQ ID NO. 3.
TGCCTAATACATGCAAGTCGAGCGAGCTTGCCTAGATGAATTTGGTGCTTGCACCAGATGAAACTAGATACAAGCGAGCGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCAAGAGACTGGGATAACACCTGGAAACAGATGCTAATACCGGATAACAACACTAGACGCATGTCTAGAGTTTAAAAGATGGTTCTGCTATCACTCTTGGATGGACCTGCGGTGCATTAGCTAGTTGGTAAGGTAACGGCTTACCAAGGCAATGATGCATAGCCGAGTTGAGAGACTGATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAGCTCTGTTGGTAGTGAAGAAAGATAGAGGTAGTAACTGGCCTTTATTTGACGGTAATTACTTAGAAAGTCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGTGCAGGCGGTTCAATAAGTCTGATGTGAAAGCCTTCGGCTCAACCGGAGAATTGCATCAGAAACTGTTGAACTTGAGTGCAGAAGAGGAGAGTGGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTCTCTGGTCTGCAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAGTGCTAAGTGTTGGGAGGTTTCCGCCTCTCAGTGCTGCAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCCAGTGCAAACCTAAGAGATTAGGTGTTCCCTTCGGGGACGCTGAGACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGTCATTAGTTGCCATCATTAAGTTGGGCACTCTAATGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGACGGTACAACGAGAAGCGAACCTGCGAAGGCAAGCGGATCTCTGAAAGCCGTTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGCTGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTCTGTAACACCCAAAGCCGGTGGGATAACCTTTATAGGAG;SEQ ID NO.3。
(3) Culture characteristics of the Strain
An LGV03 colony is picked by an inoculating loop, is subjected to zonal streaking and is inoculated on an MRS agar plate, and is cultured for 48 hours under an aerobic condition at 37 ℃; in addition, LGV03 colonies are picked and inoculated on a blood agar plate, and are cultured for 48h under anaerobic conditions at 37 ℃ by taking CICC10417 Listeria innococcus (Listeria innocus) as a negative control bacterium and CICC10473 Staphylococcus aureus (Staphylococcus aureus) as a positive control bacterium; the growth of colonies in MRS plates and the presence or absence of hemolytic ring formation on blood agar plates were observed.
The experimental results are as follows: inoculating a single LGV03 colony to an MRS solid culture medium, and carrying out anaerobic culture at 37 ℃ for 48h, wherein the colony is white, round, wet in surface, opaque and neat in edge (figure 2); the negative control bacterium cic 10417 Listeria inorage (Listeria innocus) showed no hemolytic ring on blood agar plates, while the positive control bacterium cic 10473 Staphylococcus aureus (Staphylococcus aureus) showed hemolytic ring on blood agar plates, and lactobacillus gasseri LGV03 showed no hemolytic ring on blood agar plates (fig. 3).
(4) And (3) identifying the strain morphology: when the screened LGV03 strain is observed under a microscope after gram staining, gram-positive bacteria are purple, and gram-negative bacteria are red.
The experimental results are as follows: LGV03 cells were rod-shaped, 0.4-0.5. Mu. M.times.0.9-6.3. Mu.m, aligned singly or in pairs, and gram-positive (FIG. 4).
(5) Drug sensitivity test: and taking the LGV03 strain cultured above, and determining the sensitivity of the LGV03 strain to common antibacterial drugs by adopting an E-test method.
The experimental results are as follows: as can be seen from table 2 and fig. 5, LGV03 is sensitive to penicillin, ampicillin, meropenem, vancomycin, erythromycin, linezolid, and not to clindamycin.
TABLE 2LGV03 drug sensitivity test results
Antibacterial agent | MIC value (μ g/mL) | Drug sensitivity |
Penicillin (PEN) | 0.048 | Sensitivity of |
Ampicillin (AM) | 0.19 | Sensitivity to |
Meropenem (MP) | 0.38 | Sensitivity of |
Vancomycin (VA) | 0.75 | Sensitivity of |
Erythromycin (EM) | 0.064 | Sensitivity of |
Clindamycin (CM) | 6 | Drug resistance |
Linezolid (LZ) | 0.75 | Sensitivity to |
Example 2 preparation of fermentation supernatant (extracellular secretion) and bacterial suspension (thallus) of Lactobacillus gasseri LGV03
Activating and culturing Lactobacillus gasseri LGV03, inoculating into MRS liquid culture medium, culturing at 37 deg.C for 15 hr, and regulating fermentation bacteria concentration to 2 × 10 8 Centrifuging at 4 deg.C and 8000r/min for 10min to obtain culture supernatant and thallus precipitate, and filtering with 0.22 μm filter membrane to obtain fermentation supernatant (extracellular secretion); after the cell pellet was washed twice with PBS, the cell pellet was resuspended in PBS to adjust the cell concentration to 2X 10 8 CFU/mL gave a suspension (thallus).
Example 3 Effect of Lactobacillus gasseri LGV03 on the stimulation of Tryptase secretion by Compoud48/80 Zebra fish
Cromolyn sodium and Na-benzoyl-DL-arginine-p-nitroamide hydrochloride (BAPNA) were purchased from Shanghai leaf Biotech, inc., compoud48/80 was purchased from Sigma-Aldrich.
Healthy wild-type AB line zebrafish developed to 5dpf (days post fertilization) were picked and placed 10 strips/well in 96-well cell culture plates. The experiment set comprises a normal group, a model group, an intervention group (a positive control group, a bacterial suspension group and a fermentation supernatant group) and a solvent zero-adjustment group, wherein each group is provided with 6 multiple wells. Adding PBS into a normal group, adding PBS into a model group, adding a sodium cromoglycate solution (100 mu g/mL) into a positive control group, adding a bacterial suspension into a bacterial suspension group, adding a fermentation supernatant into a fermentation supernatant group, adding PBS into a solvent zeroing group (without adding zebra fish), and adding 100 mu L of PBS into each hole; after incubation for 24h at 28 ℃ in a biochemical incubator, 150 mu LPBS is added to a normal group, compoud48/80 (8 mu g/mL) is added to a model group, a bacterial suspension group, a fermentation supernatant group, a positive control group and a solvent zero-adjustment group respectively, 150 mu L of the solution is added to each well, after incubation for 2h at 28 ℃, 150 mu L of the solution is taken from each well and is placed in a centrifuge tube of 2mL respectively, 150 mu LBAPNA solution (20 mg/mL) is added to each centrifuge tube, after incubation for 48h at 37 ℃ in the biochemical incubator, 200 mu L of the solution is taken from each centrifuge tube and is placed in a cell culture plate of 96 wells, and the absorbance (OD value) is measured at 405nm by an enzyme labeling instrument. The expression level and inhibition rate of Tryptase are as follows:
the data were statistically processed using SPSS19.0 software, and the experimental data were expressed as x + -SEM data and analyzed by one-way anova. Compared to the normal group: ### p<0.005; compared to the model group: * P is<0.05,**P<0.01,***P<0.005。
The results of the expression level and inhibition rate of Tryptase are shown in FIGS. 6 and 7, and the results show that the Tryptase secretion amount (172.96 +/-8.02%) of the model group is obviously increased compared with that of the normal group (44.64 +/-4.44%), which indicates that the Compoud48/80 stimulation is effective.
The Tryptase secretion amount of the sodium cromoglycate group is 55.18 +/-3.03%, the Tryptase inhibition rate is 68.10 +/-1.75%, and the difference is obvious compared with that of a model group (the Tryptase secretion amount is 172.96 +/-8.02%, and the Tryptase inhibition rate is 0) (P is less than 0.005). Therefore, the cromolyn sodium can inhibit the degranulation of mast cells in vivo, has an anti-sensitization effect, and is consistent with clinical results. The secretion amounts of Tryptose of the fermentation supernatant and the bacterial suspension group of the Lactobacillus gasseri LGV03 are respectively 79.78 +/-3.89% and 122.00 +/-6.52%, and the inhibition rates of the Tryptose are respectively 53.88 +/-2.25% and 29.47 +/-3.77%, so that the differences (P < 0.005) between the secretion amounts of the Tryptose and the inhibition rates of the Tryptose are obvious compared with those of a model group (the secretion amounts of the Tryptose are 172.96 +/-8.02% and the inhibition rates of the Tryptose are 0). Therefore, the results show that the fermentation supernatant and the bacterial suspension of the lactobacillus gasseri LGV03 can inhibit the degranulation of mast cells in vivo and show good effect of preventing anaphylactic reaction.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Sequence listing
<110> southern medical university Hospital in south China sea (third Hospital in south sea area of Buddha city)
<120> Lactobacillus gasseri LGV03 and application thereof
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 1
<210> 2
<211> 19
<212> DNA
<213> Artificial Sequence
<400> 2
ggttaccttg ttacgactt 19
<210> 3
<211> 1444
<212> DNA
<213> Artificial Sequence
<400> 3
tgcctaatac atgcaagtcg agcgagcttg cctagatgaa tttggtgctt gcaccagatg 60
aaactagata caagcgagcg gcggacgggt gagtaacacg tgggtaacct gcccaagaga 120
ctgggataac acctggaaac agatgctaat accggataac aacactagac gcatgtctag 180
agtttaaaag atggttctgc tatcactctt ggatggacct gcggtgcatt agctagttgg 240
taaggtaacg gcttaccaag gcaatgatgc atagccgagt tgagagactg atcggccaca 300
ttgggactga gacacggccc aaactcctac gggaggcagc agtagggaat cttccacaat 360
ggacgcaagt ctgatggagc aacgccgcgt gagtgaagaa gggtttcggc tcgtaaagct 420
ctgttggtag tgaagaaaga tagaggtagt aactggcctt tatttgacgg taattactta 480
gaaagtcacg gctaactacg tgccagcagc cgcggtaata cgtaggtggc aagcgttgtc 540
cggatttatt gggcgtaaag cgagtgcagg cggttcaata agtctgatgt gaaagccttc 600
ggctcaaccg gagaattgca tcagaaactg ttgaacttga gtgcagaaga ggagagtgga 660
actccatgtg tagcggtgga atgcgtagat atatggaaga acaccagtgg cgaaggcggc 720
tctctggtct gcaactgacg ctgaggctcg aaagcatggg tagcgaacag gattagatac 780
cctggtagtc catgccgtaa acgatgagtg ctaagtgttg ggaggtttcc gcctctcagt 840
gctgcagcta acgcattaag cactccgcct ggggagtacg accgcaaggt tgaaactcaa 900
aggaattgac gggggcccgc acaagcggtg gagcatgtgg tttaattcga agcaacgcga 960
agaaccttac caggtcttga catccagtgc aaacctaaga gattaggtgt tcccttcggg 1020
gacgctgaga caggtggtgc atggctgtcg tcagctcgtg tcgtgagatg ttgggttaag 1080
tcccgcaacg agcgcaaccc ttgtcattag ttgccatcat taagttgggc actctaatga 1140
gactgccggt gacaaaccgg aggaaggtgg ggatgacgtc aagtcatcat gccccttatg 1200
acctgggcta cacacgtgct acaatggacg gtacaacgag aagcgaacct gcgaaggcaa 1260
gcggatctct gaaagccgtt ctcagttcgg actgtaggct gcaactcgcc tacacgaagc 1320
tggaatcgct agtaatcgcg gatcagcacg ccgcggtgaa tacgttcccg ggccttgtac 1380
acaccgcccg tcacaccatg agagtctgta acacccaaag ccggtgggat aacctttata 1440
ggag 1444
Claims (4)
1. The application of Lactobacillus gasseri LGV03 in the preparation of drugs for preventing allergic diseases is characterized in that the preservation number of the Lactobacillus gasseri LGV03 is CGMCC No.22010.
2. Use of lactobacillus gasseri LGV03 for the preparation of a medicament for the prevention of allergic disease according to claim 1, wherein said lactobacillus gasseri LGV03 is a bacterial suspension.
3. Use of lactobacillus gasseri LGV03 according to claim 1 for the preparation of a medicament for inhibiting mast cell degranulation.
4. Use of a lactobacillus gasseri LGV03 for the manufacture of a medicament for inhibiting mast cell degranulation according to claim 3, wherein said lactobacillus gasseri LGV03 is a bacterial suspension.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110523517.9A CN113215045B (en) | 2021-05-13 | 2021-05-13 | Lactobacillus gasseri LGV03 and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110523517.9A CN113215045B (en) | 2021-05-13 | 2021-05-13 | Lactobacillus gasseri LGV03 and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113215045A CN113215045A (en) | 2021-08-06 |
CN113215045B true CN113215045B (en) | 2023-03-28 |
Family
ID=77095685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110523517.9A Active CN113215045B (en) | 2021-05-13 | 2021-05-13 | Lactobacillus gasseri LGV03 and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113215045B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114129601B (en) * | 2021-12-22 | 2024-03-08 | 南方医科大学第七附属医院(佛山市南海区第三人民医院) | Application of lactobacillus gasseri LGV03 in preparation of medicine for preventing or treating HPV infection |
CN116004465A (en) * | 2023-01-06 | 2023-04-25 | 上海上药信谊药厂有限公司 | Lactobacillus gasseri and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5937015B2 (en) * | 2010-12-16 | 2016-06-22 | 株式会社明治 | Delayed type hypersensitivity reducing agent |
TWI619507B (en) * | 2013-03-22 | 2018-04-01 | 東宇生物科技股份有限公司 | Active ingredient for treatment or prevention of allergic diseases |
CN107669706A (en) * | 2017-11-18 | 2018-02-09 | 宁波绿康康复科技有限公司 | Compound probiotic for treating and preventing anaphylactia and preparation method thereof and type agent |
CN112469812B (en) * | 2018-05-23 | 2024-01-12 | Ko生物技术有限公司 | Lactobacillus gasseri KBL697 strain and application thereof |
CN112159784A (en) * | 2020-10-29 | 2021-01-01 | 佛山市朗芯生物科技有限公司 | Bifidobacterium longum NX-4 and application thereof in preparing medicament for treating and/or preventing allergic diseases |
-
2021
- 2021-05-13 CN CN202110523517.9A patent/CN113215045B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN113215045A (en) | 2021-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113215045B (en) | Lactobacillus gasseri LGV03 and application thereof | |
CN113088463B (en) | Lactobacillus acidophilus with probiotic characteristics and application thereof | |
CN109182164B (en) | Lactobacillus reuteri strain and application thereof in bee breeding process | |
CN111826315A (en) | Lactobacillus rhamnosus NX-2 and application thereof in preparation of uric acid reducing medicines | |
CN112725219B (en) | Bifidobacterium adolescentis strain and application thereof | |
CN114292781B (en) | Bifidobacterium longum SYSU-02 and application thereof | |
CN112159784A (en) | Bifidobacterium longum NX-4 and application thereof in preparing medicament for treating and/or preventing allergic diseases | |
CN106011040B (en) | One plant degradation Ofloxacin anthropi and its application | |
CN113862188A (en) | Lactobacillus gasseri LS03 and application thereof | |
CN115851551B (en) | Pediococcus pentosaceus A21358 with helicobacter pylori resisting effect and application thereof | |
CN115029260B (en) | Lactobacillus gasseri with anti-inflammatory and antioxidant properties and application thereof | |
CN114350555B (en) | Lactobacillus paracasei lp.R3 and application thereof in preparation of immunity-improving drugs | |
CN105779346B (en) | A kind of enterococcus faecium and its application of bacteriocinogeny | |
US11786568B2 (en) | Strain of caucasus yoghurt lactobacillus MSR101 and use thereof | |
CN112251380A (en) | Lactobacillus plantarum FLPL05 for promoting body health and longevity | |
KR101201420B1 (en) | A feed additive containing novel Lactobacillus jonhsonnii | |
CN115025130A (en) | Application of lactobacillus reuteri E9 in preparing medicine for treating or preventing allergic diseases | |
CN115747107A (en) | Lactobacillus casei LS02 and application thereof in preparing medicament for treating or preventing allergic diseases | |
CN110835620A (en) | Lactobacillus plantarum and application thereof | |
CN115895966A (en) | Bifidobacterium bifidum BL002 for assisting in relieving gout and application thereof | |
CN113046276B (en) | Breast milk source lactobacillus rhamnosus and application thereof | |
CN104195093A (en) | Lactobacillus salivarius and pharmaceutical application thereof | |
CN116376758B (en) | Lactobacillus jensenii LS06 and application thereof in preparation of medicines for treating or preventing allergic diseases | |
CN117487725B (en) | Lactobacillus acidophilus with immunity regulating effect and application thereof | |
CN114806953B (en) | Lactobacillus gasseri with effect of improving type 1 diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 528200 No. 28, Desheng section, Liguan Road, Lishui Town, Nanhai District, Foshan City, Guangdong Province Applicant after: The seventh Affiliated Hospital of Southern Medical University (the third people's Hospital of Nanhai District Foshan City) Address before: 528200 No. 28, Desheng section, Liguan Road, Lishui Town, Nanhai District, Foshan City, Guangdong Province Applicant before: NANHAI HOSPITAL OF SOUTHERN MEDICAL University (THE THIRD PEOPLE'S HOSPITAL OF NANHAI DISTRICT FOSHAN CITY) |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |